MS: New Dosing, A New Withdrawal MS: New Dosing, A New Withdrawal

Cutting the risk for natalizumab-related PML, update on disability outcomes with ibudilast, and daclizumab pulled from the global market.Medscape Neurology
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Neurology & Neurosurgery Commentary Source Type: news